Can simvastatin improve erectile function and health-related quality of life in men aged ≥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]

BJU International

Volumn 111, Issue 2, 2013, Pages 324-333

  Trivedi, Daksha ^a   Kirby, Michael ^a   Wellsted, David M ^a   Ali, Shehzad ^b   Hackett, Geoffrey ^c   O'Connor, Bernadette ^a   Van Os, Sandra ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

erectile dysfunction; randomized controlled trial; statins

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERECTILE DYSFUNCTION; EUROQOL EQ-5D; HEALTH CARE COST; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MED-QOL; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PENIS ERECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADULT; AGED; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; HEALTH STATUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMPOTENCE, VASCULOGENIC; MALE; MIDDLE AGED; PATIENT SATISFACTION; PENILE ERECTION; QUALITY OF LIFE; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84873128278     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11241.x     Document Type: Article

References (35)

1. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328-338
2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U,. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-311
3. Laumann EO, Paik A, Rosen RC,. Sexual dysfunction in the United States. Prevalence and predictors. JAMA 1999; 281: 537-544
4. Dunn KM, Croft PR, Hackett GI,. Sexual problems: a study of prevalence and need for health care in the general population. Fam Pract 1998; 15: 519-524
5. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA,. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002
6. Litwin MS, Nied RJ, Dhanani N,. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med 1998; 13: 159-166
7. Speel TGW, van Langen H, Meuleman EJH,. The risk of coronary heart disease in men with erectile dysfunction. Eur Urol 2003; 44: 366-371
8. Wilson EC, McKeen ES, Scuffham PA, Brown MC, Wylie K, Hackett G,. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Pharmcoeconomics 2002; 20: 879-889
9. British Society for Sexual Medicine. Guidelines on the management of erectile dysfunction. 2007. Available at: http://www.bssm.org.uk/downloads/BSSM- ED-Management-Guidelines-2007.pdf. Accessed 3 February 2012
10. Sullivan ME, Keoghane SR, Miller MAW,. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87: 838-845
11. Fung MM, Bettencourt R, Barrett-Connor E,. Heart disease risk factors predict erectile dysfunction 25 years later. The Rancho Bernardo Study. J Am Coll Cardiol 2004; 43: 1405-1411
12. Tikkanen MJ, Jackson G, Tammela T, et al. Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention. Int J Clin Pract 2007; 61: 265-268
13. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R,. Erectile dysfunction is a marker for cardiovascular disease: results of the Minority Health Institute Expert Advisory Panel. J Sex Med 2005; 2: 40-52
14. Walczak MK, Lokhandwala N, Hodge MB, Guay AT,. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5: 19-24
15. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-379
16. Saltzman EA, Guay AT, Jacobson J,. Improvement in erectile dysfunction in men with organic erectile dysfunction by correlation of elevated cholesterol levels: a clinical observation. J Urol 2004; 172: 255-258
17. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB,. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
18. Montorsi P, Montorsi F, Schulman CC,. Is erectile dysfunction the 'tip of the iceberg' of a systemic vascular disorder? Eur Urol 2003; 44: 352-354
19. Moore RA,. Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2002; 2: 6. doi: 10.1186/1471-2490-2-6
20. Masumoto A, Hirooka Y, Hironaga K, et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001; 88: 1291-1294
21. Herrmann HC, Levine LA, Macaluso J Jr, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and Pilot Trial Results. J Sex Med 2006; 3: 303-308
22. Yaman O, Akand M, Gursoy A, Erdogan MF, Anafarta K,. The effect of diabetes mellitus treatment and good glycaemic control on the erectile function in men with diabetes mellitus-induced erectile dysfunction: a pilot study. J Sex Med 2006; 3: 344-348
23. Gokkaya SC, Ozden C, Levent Ozdal O, Hakan Koyuncu H, Guzel O, Memis A,. Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction. Scand J Urol Nephrol 2008; 42: 437-440
24. Trivedi D, Kirby M, Norman F, Przybytniak I, Ali S, Wellsted DM,. Can simvastatin improve erectile function and health-related quality of life in men aged > 40 years with erectile dysfunction? Rationale and design of the Erectile Dysfunction and Statins (EDS) Trial [ISRCTN66772971 ]. BJU Int 2011; 108: 1850-1854
25. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM,. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile function. Int J Impot Res 1999; 11: 319-326
26. Wagner TH, Patrick DL, McKenna SP, Froese PS,. Cross-cultural development of a quality of life measure for men with erection difficulties. Qual Life Res 1996; 5: 443-449
27. Brooks R, Rabin R, de, Charro F, eds. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective: Evidence from the EuroQol BIO MED Research Programme. Rotterdam: Kluwer Academic Publishers, 2003
28. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity and augmentation index in healthy humans. Hypertension 2006; 48: 602-608
29. Baigent C, Landray MJ, Reith C, et al. SHARP collaborators). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
30. Gupta BP, Murad H, Clifton M, Prokop L, Nehra A, Kopecky SL,. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction. A systematic review and meta-analysis. Arch Intern Med 2011; 171: 1797-1803
31. Koskimaki J, Shiri R, Tammela T, Häkkinen J, Hakama M, Auvinen A,. Regular intercourse protects against erectile dysfunction: Tampere Aging Male Urologic Study. Am J Med 2008; 121: 592-596
32. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl. 5): V1-52
33. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR,. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-1665
34. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701
35. Stanworth RD, Kapoor D, Channer KS, Hugh Jones T,. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009; 32: 541-546